Den samlede incidens af vaccinerelaterede bivirkninger på indstiksstedet var signifikant højere for patienter vaccineret med ZOSTAVAX end for patienter, som fik placebo (48% for ZOSTAVAX og 17% for placebo).
The overall incidence of vaccine-related injection-site adverse reactions was significantly greater for subjects vaccinated with ZOSTAVAX versus subjects who received placebo (48% for ZOSTAVAX and 17% for placebo).